CN113241187A - Diagnostic kit - Google Patents
Diagnostic kit Download PDFInfo
- Publication number
- CN113241187A CN113241187A CN202110641819.6A CN202110641819A CN113241187A CN 113241187 A CN113241187 A CN 113241187A CN 202110641819 A CN202110641819 A CN 202110641819A CN 113241187 A CN113241187 A CN 113241187A
- Authority
- CN
- China
- Prior art keywords
- coronavirus
- patient
- content
- patients
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention specifically discloses a diagnostic kit which comprises a reagent for measuring blood indexes, wherein the blood indexes comprise at least one of platelet content, blood sugar content, total cholesterol content, high-density lipoprotein content, low-density lipoprotein content, prothrombin time, D-dimer content and DIC score, and the diagnostic kit judges the severity of a coronavirus patient according to the measured blood indexes. The diagnosis kit can accurately judge the severity of the coronavirus patient, and effectively solves the problem that the treatment of the coronavirus patient by using clinical phenotype has certain hysteresis in the prior art.
Description
Technical Field
The invention relates to the technical field of biomedical engineering, in particular to a diagnostic kit, and especially relates to application of a diagnostic kit for determining blood indexes in judging the severity of a coronavirus patient.
Background
The human disease caused by coronaviruses is mainly respiratory infection (including severe acute respiratory syndrome, SARS). The virus is very temperature sensitive and due to this property, winter and early spring are the epidemic seasons of the viral disease. Coronavirus is one of the main pathogens of acute exacerbation of patients with common cold and chronic tracheitis of adults, mainly causes upper respiratory tract infection, and generally rarely affects lower respiratory tract. In addition, it can also cause acute gastroenteritis of infants and newborn infants, and the main symptoms are watery stool, fever and vomiting, which can be pulled for more than 10 times every day, and serious patients even have watery stool in blood, and rarely cause nervous system syndrome.
The etiological agent of the novel coronavirus pneumonia (COVID-19) has been identified as a novel coronavirus, now known as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the diagnosis and treatment scheme for novel coronavirus pneumonia (trial seventh edition) issued by the national health and health committee, the new crown types of different clinical manifestations can be classified into light type, common type, heavy type and dangerous type. Most infected patients exhibit non-specific symptoms such as fever, dry cough, and fatigue. The prognosis of most patients is good, and some patients with severe disease can rapidly develop acute respiratory distress syndrome, septic shock, metabolic acidosis, blood coagulation dysfunction and even die. However, clinical typing of patients with pneumonia is based on clinical phenotypes, which are often caused by changes in the patient's internal environment, and clinical phenotypes alone have some hysteresis in the treatment of new coronary pneumonia. Therefore, the detection of the severity of the new coronavirus through the change of the endogenous index plays an important role.
In view of this, it is a technical problem to be urgently needed by those skilled in the art to research a kit for diagnosing the severity of a patient infected with coronavirus, which is prepared by using a reagent for detecting a blood index, so as to effectively detect the severity of the patient infected with coronavirus.
Disclosure of Invention
The invention aims to provide application of a reagent for detecting a blood index in preparing a diagnostic kit for diagnosing the severity of a patient infected with coronavirus, and the severity of the patient infected with coronavirus is judged by detecting the blood index of the patient infected with coronavirus through the diagnostic kit.
In order to solve the above technical problems, the present invention provides a diagnostic kit for measuring a blood index, the diagnostic kit comprising a reagent for measuring a blood index, the blood index including at least one of a platelet content, a blood glucose content, a total cholesterol content, a high density lipoprotein content, a low density lipoprotein content, a prothrombin time, a D-dimer content, and a DIC score, the diagnostic kit judging the severity of a coronavirus patient based on the measured blood index.
Preferably, the specific implementation manner of the diagnostic kit for determining the severity of the coronavirus patient comprises:
a. when the platelet content of patients with coronavirus is below 180 × 10 within 2-20 days9When the patient is one or more times, the patient with the coronavirus can be judged as a critical patient; when the platelet content of patients with coronavirus is below 100 × 10 within 2-20 days9When the number of patients is one liter, the severity of the coronavirus infection patient is judged to continuously increase and the coronavirus infection patient tends to die; and/or
b. When the blood sugar content of the coronavirus patient is more than 7.5mmol/L within 2-20 days, the coronavirus patient can be judged to be a critical patient; when the blood sugar content of the patients with coronavirus is more than 11.0mmol/L within 2-20 days, the severity of the patients with coronavirus infection is judged to continuously increase and tend to die; and/or
c. When the total cholesterol content of the coronavirus patients is lower than 3.31mmol/L within 2-20 days, the coronavirus infected patients can be judged to be critical patients; and/or
d. When the content of the high-density lipoprotein in the coronavirus patient is lower than 0.64mmol/L within 2-20 days, the coronavirus infected patient can be judged as a critical patient; and/or
e. When the content of the low-density lipoprotein in the coronavirus patient is lower than 1.43mmol/L within 2-20 days, the coronavirus infected patient can be judged as a critical patient; and/or
f. Within 2-20 days, when the prothrombin time of the coronavirus patient is more than 14 seconds, the coronavirus patient can be judged to be a critical patient; when the prothrombin time of a coronavirus patient is greater than 16 seconds and lasts for more than 5 days, the coronavirus infected patient can be judged to have continuously increased critical degree and tend to die; and/or
g. When the D-dimer content of the coronavirus patient is more than 2g/L within 2-20 days, judging the coronavirus patient to be a critical patient; when the D-dimer content of a coronavirus patient is more than 3g/L and lasts for more than 4 days, the coronavirus infected patient can be judged to have continuously increased critical degree and tend to die; and/or
h. Within 2-20 days, when the DIC score of the coronavirus patient is not lower than 5, the coronavirus patient can be determined to be a critical patient.
The diagnosis kit is used for detecting the blood indexes (at least one of platelet content, blood sugar content, total cholesterol content, high-density lipoprotein content, low-density lipoprotein content, prothrombin time, D-dimer content and DIC score) of the coronavirus patients, so that the severity of the coronavirus patients is judged by using the detected blood indexes, the severity of the coronavirus patients is judged by using endogenous indexes, and the diagnosis kit has the characteristics of accuracy, timeliness and high efficiency.
Drawings
FIG. 1 shows a schematic representation of the variation of the platelet content after admission to a hospital in patients with different types of novel coronaviruses,
FIG. 2 is a schematic diagram showing the change of platelet content before discharge of a critically ill novel coronavirus patient,
FIG. 3 shows a schematic representation of the variation of blood glucose levels after admission of patients with different types of novel coronaviruses,
FIG. 4 is a schematic diagram showing the change of blood sugar content of a critically ill novel coronavirus patient before discharge,
FIG. 5 shows a schematic representation of the variation of total cholesterol levels after admission in patients with different types of novel coronaviruses,
FIG. 6 is a schematic diagram showing the variation of the high density lipoprotein content of different types of patients with the novel coronavirus,
FIG. 7 is a graph showing the change in low density lipoprotein levels after admission of different types of patients with the novel coronavirus,
FIG. 8 shows a schematic representation of the prothrombin time profile after admission to a patient with different types of novel coronaviruses,
FIG. 9 is a schematic diagram showing the change of prothrombin time before discharge of a critically novel coronavirus patient,
FIG. 10 shows a schematic representation of the variation of D-dimer content after admission to a hospital for different types of patients with the novel coronavirus,
FIG. 11 is a graph showing the change in D-dimer content before discharge of a critically novel coronavirus patient,
FIG. 12 is a graph showing the change in DIC (dispersed intravascular coagulation) score after admission of patients with different types of novel coronaviruses,
FIG. 13 is a graph showing the change in DIC score before discharge of a critically ill novel coronavirus patient.
Detailed Description
In order to make the technical solutions of the present invention better understood, the present invention is further described in detail below with reference to the accompanying drawings.
In this example, the patients with coronavirus were novel coronavirus (COVID-19) patients.
In this embodiment, the diagnostic kit comprises a reagent for measuring a blood index including at least one of platelet content, blood glucose content, total cholesterol content, high density lipoprotein content, low density lipoprotein content, prothrombin time, D-dimer content, and DIC score, and the diagnostic kit determines the severity of the coronavirus patient based on the measured blood index.
Specifically, the diagnostic kit samples and measures blood of patients with the novel coronavirus (COVID-19) with different severity degrees, and then obtains corresponding blood index data, and the diagnostic kit judges the severity degree of the patients with the novel coronavirus according to at least one measured blood index.
The diagnosis kit judges the severity of the coronavirus patient according to the at least one blood index determined by the above steps, and the specific implementation mode comprises:
a. when the platelet content of patients with coronavirus is below 180 × 10 within 2-20 days9When the patient is one or more times, the patient with the coronavirus can be judged as a critical patient; when the platelet content of patients with coronavirus is below 100 × 10 within 2-20 days9When the number of patients is one liter, the severity of the coronavirus infection patient is judged to continuously increase and the coronavirus infection patient tends to die; as shown in FIGS. 1 and 2, it can be seen from the data in FIG. 1 that the platelet content in the body of the critically ill novel coronavirus patient was greatly reduced to a value of about 172.5X 10 within 2 to 20 days after the patient was admitted9The value of the platelet content in the body is about 230 x 10 within 2-20 days after the patient with the common type or the severe type novel coronavirus is admitted9Per liter; as can be seen from the data in FIG. 2, as the risk of the critically ill patients with the novel coronavirus continued to increase and approached the death endpoint, the platelet content in the body decreased significantly, which is about 62X 109Platelet content in critically ill patients is about 142X 10/liter9One for each liter.
b. When the blood sugar content of the coronavirus patient is more than 7.5mmol/L within 2-20 days, the coronavirus patient can be judged to be a critical patient; when the blood sugar content of the patients with coronavirus is more than 11.0mmol/L within 2-20 days, the severity of the patients with coronavirus infection is judged to continuously increase and tend to die; as shown in FIGS. 3 and 4, it can be seen from the data in FIG. 3 that the blood sugar level of the critically ill novel coronavirus patients in the patients' bodies is greatly increased after the patients are admitted, and the blood sugar level is about 7.56mmol/L, while the blood sugar level of the patients of the ordinary or severe novel coronavirus patients is between 5.59 and 6.64 mmol/L; as can be seen from the data in FIG. 4, as the risk of critically ill patients with the novel coronavirus increased and approached the death endpoint, the blood glucose level in the body increased greatly, which was about 12.6mmol/L, while critically ill patients who survived continued to be about 8 mmol/L.
c. When the total cholesterol content of the coronavirus patients is lower than 3.31mmol/L within 2-20 days, the coronavirus infected patients can be judged to be critical patients; as shown in FIG. 5, it can be seen from the data in FIG. 5 that the total cholesterol level in the patient with the novel coronavirus was significantly reduced after the patient with the severe coronavirus was admitted, particularly after the intermediate stage of admission (day 6), the total cholesterol level in the patient was only about 3.31mmol/L, and the total cholesterol level in the patient with the novel coronavirus, which was normal type or severe type, was between 3.71 mmol/L and 3.95 mmol/L.
d. When the content of the high-density lipoprotein in the coronavirus patient is lower than 0.64mmol/L within 2-20 days, the coronavirus infected patient can be judged as a critical patient; as shown in FIG. 6, it can be seen from the data in FIG. 6 that the high-density lipoprotein content in the patients with the severe form of the novel coronavirus showed a significant decrease after admission, particularly after the middle stage of admission (day 9), which was only about 0.64mmol/L, whereas that in the patients with the normal form or the severe form of the novel coronavirus was about 1.12 mmol/L.
e. When the content of the low-density lipoprotein in the coronavirus patient is lower than 1.43mmol/L within 2-20 days, the coronavirus infected patient can be judged as a critical patient; as shown in FIG. 7, it can be seen from the data in FIG. 7 that the low-density lipoprotein content in the patient with the severe form of the novel coronavirus showed a significant decrease after admission, particularly after the mid-hospital period (day 22), which was only about 1.43mmol/L, whereas the low-density lipoprotein content in the patient with the normal form or the severe form of the novel coronavirus was 2.89 mmol/L.
f. Within 2-20 days, when the prothrombin time of the coronavirus patient is more than 14 seconds, the coronavirus patient can be judged to be a critical patient; when the prothrombin time of a coronavirus patient is greater than 16 seconds and lasts for more than 5 days, the coronavirus infected patient can be judged to have continuously increased critical degree and tend to die; as shown in fig. 8 and 9, it can be seen from the data in fig. 8 that the prothrombin time in vivo was prolonged to 15 seconds after the patient with the severe new coronavirus was admitted, whereas the prothrombin time in vivo was only 14 seconds after the patient with the normal or severe new coronavirus was admitted; as can be seen from the data in fig. 9, as the risk of critically ill patients with the novel coronavirus increased and approached the death endpoint, the prothrombin time in the body was significantly increased, with a value of 18 seconds, while the prothrombin time in critically ill surviving patients had a value of about 14.7 seconds.
g. When the D-dimer content of the coronavirus patient is more than 2g/L within 2-20 days, judging the coronavirus patient to be a critical patient; when the D-dimer content of a coronavirus patient is more than 3g/L and lasts for more than 4 days, the coronavirus infected patient can be judged to have continuously increased critical degree and tend to die; as shown in FIGS. 10 and 11, it can be seen from the data in FIG. 10 that the D-dimer content of the critically ill novel coronavirus patients significantly increased after admission to the hospital, and the D-dimer content of the critically ill novel coronavirus patients was about 2.6g/L or more, while the D-dimer content of the patients of normal or severe novel coronavirus patients was less than 1.5g/L after admission to the hospital; as can be seen from the data in FIG. 11, as the risk of critically ill patients with the novel coronavirus increased and approached the death endpoint, the D-dimer content in the patients with the novel coronavirus was about 8.8g/L, showing a significant increase, while the D-dimer content in the critically alive patients was only about 1.5 g/L.
h. Within 2-20 days, when the DIC score of the coronavirus patient is not lower than 5, the coronavirus patient can be determined to be a critical patient. As shown in fig. 12 and 13, it can be seen from the data in fig. 12 that when the critically ill novel coronavirus patient is admitted, the DIC score thereof is increased to 5 points, while the DIC score of the patient with normal or severe novel coronavirus is less than 5 points; as can be seen from the data in FIG. 13, as the risk of the critically ill novel coronavirus patients increases and approaches the death endpoint, the DIC score increases to 6 points, while the DIC score of critically ill living patients decreases to 4 points, and thus, when the DIC score of critically ill novel coronavirus patients after admission is not less than 5 points and continues, it can be determined that the risk is increased and death is prone to occur.
In this example, in order to verify the technical effects of the present invention, in the period from the time when the patient with the novel coronavirus is admitted to the hospital to the time when the patient is discharged from the hospital, the clinical indexes (including but not limited to respiration rate, finger oxygen saturation, arterial oxygen partial pressure and oxygen uptake concentration, fever and imaging change, etc.) of the novel coronavirus patients are observed, the novel coronavirus patients with different clinical manifestations are typed according to the observed clinical index data and a novel coronavirus pneumonia diagnosis and treatment plan (trial seventh edition) issued by the national health committee, and the results are displayed, the typing result of the novel coronavirus patient by the clinical index data is completely consistent with the typing result of the diagnosis kit for judging the severity of the coronavirus infected patient, therefore, the technical scheme provided by the invention has the characteristics of timeliness, accuracy and high efficiency.
The above description details a diagnostic kit provided by the present invention. The principles and embodiments of the present invention are explained herein using specific examples, which are presented only to assist in understanding the core concepts of the present invention. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.
Claims (2)
1. A diagnostic kit comprising reagents for determining a blood index comprising at least one of platelet content, blood glucose content, total cholesterol content, high density lipoprotein content, low density lipoprotein content, prothrombin time, D-dimer content and DIC score, the diagnostic kit determining the severity of a coronavirus patient based on the determined blood index.
2. The diagnostic kit of claim 1, wherein the specific implementation of the diagnostic kit for determining the severity of a coronavirus patient comprises:
a. when the platelet content of patients with coronavirus is below 180 × 10 within 2-20 days9When the patient is one or more times, the patient with the coronavirus can be judged as a critical patient; when the platelet content of patients with coronavirus is below 100 × 10 within 2-20 days9When the number of patients is one liter, the severity of the coronavirus infection patient is judged to continuously increase and the coronavirus infection patient tends to die; and/or
b. When the blood sugar content of the coronavirus patient is more than 7.5mmol/L within 2-20 days, the coronavirus patient can be judged to be a critical patient; when the blood sugar content of the patients with coronavirus is more than 11.0mmol/L within 2-20 days, the severity of the patients with coronavirus infection is judged to continuously increase and tend to die; and/or
c. When the total cholesterol content of the coronavirus patients is lower than 3.31mmol/L within 2-20 days, the coronavirus infected patients can be judged to be critical patients; and/or
d. When the content of the high-density lipoprotein in the coronavirus patient is lower than 0.64mmol/L within 2-20 days, the coronavirus infected patient can be judged as a critical patient; and/or
e. When the content of the low-density lipoprotein in the coronavirus patient is lower than 1.43mmol/L within 2-20 days, the coronavirus infected patient can be judged as a critical patient; and/or
f. Within 2-20 days, when the prothrombin time of the coronavirus patient is more than 14 seconds, the coronavirus patient can be judged to be a critical patient; when the prothrombin time of a coronavirus patient is greater than 16 seconds and lasts for more than 5 days, the coronavirus infected patient can be judged to have continuously increased critical degree and tend to die; and/or
g. When the D-dimer content of the coronavirus patient is more than 2g/L within 2-20 days, judging the coronavirus patient to be a critical patient; when the D-dimer content of a coronavirus patient is more than 3g/L and lasts for more than 4 days, the coronavirus infected patient can be judged to have continuously increased critical degree and tend to die; and/or
h. Within 2-20 days, when the DIC score of the coronavirus patient is not lower than 5, the coronavirus patient can be determined to be a critical patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010606856.9A CN111681768A (en) | 2020-06-29 | 2020-06-29 | Application of blood index in detecting severity of coronavirus infection patient |
| CN2020106068569 | 2020-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113241187A true CN113241187A (en) | 2021-08-10 |
Family
ID=72437376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010606856.9A Pending CN111681768A (en) | 2020-06-29 | 2020-06-29 | Application of blood index in detecting severity of coronavirus infection patient |
| CN202110641819.6A Pending CN113241187A (en) | 2020-06-29 | 2021-06-09 | Diagnostic kit |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010606856.9A Pending CN111681768A (en) | 2020-06-29 | 2020-06-29 | Application of blood index in detecting severity of coronavirus infection patient |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111681768A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113138250B (en) * | 2021-04-23 | 2021-12-17 | 西湖大学 | Non-diagnostic method for typing covid-19 grade by using characteristic urine protein and application |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2481114A1 (en) * | 2001-04-12 | 2002-10-24 | 1411198 Ontario Limited | Cardiovascular disease and thrombotic risk diagnostic tests |
| CA2418004A1 (en) * | 2003-01-24 | 2004-07-24 | Guy Boivin | Multiplex assays for detection and identification of viral respiratory pathogens |
| CN101441219A (en) * | 2007-11-20 | 2009-05-27 | 山东泰邦生物制品有限公司 | Coronary heart disease and palsy risk diagnosis reagent kit and manufacturing method thereof |
| JP2010169696A (en) * | 2010-05-10 | 2010-08-05 | Denka Seiken Co Ltd | Method for diagnosing arteriosclerosis |
| WO2013050731A1 (en) * | 2011-10-05 | 2013-04-11 | The Binding Site Group Limited | Prognostic method for diabetes |
| CA2771954A1 (en) * | 2012-03-20 | 2013-09-20 | Matthew Simon Byers | Pneumonia biomarkers |
| US20190025328A1 (en) * | 2015-10-27 | 2019-01-24 | Abbott Laboratories | Troponin i and soluble urokinase receptor detection for determining the risk of cardiovascular disease |
| US20190307405A1 (en) * | 2018-04-10 | 2019-10-10 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
| CN111254228A (en) * | 2020-05-06 | 2020-06-09 | 上海思路迪医学检验所有限公司 | Kit for detecting novel coronavirus and influenza virus |
-
2020
- 2020-06-29 CN CN202010606856.9A patent/CN111681768A/en active Pending
-
2021
- 2021-06-09 CN CN202110641819.6A patent/CN113241187A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2481114A1 (en) * | 2001-04-12 | 2002-10-24 | 1411198 Ontario Limited | Cardiovascular disease and thrombotic risk diagnostic tests |
| CA2418004A1 (en) * | 2003-01-24 | 2004-07-24 | Guy Boivin | Multiplex assays for detection and identification of viral respiratory pathogens |
| CN101441219A (en) * | 2007-11-20 | 2009-05-27 | 山东泰邦生物制品有限公司 | Coronary heart disease and palsy risk diagnosis reagent kit and manufacturing method thereof |
| JP2010169696A (en) * | 2010-05-10 | 2010-08-05 | Denka Seiken Co Ltd | Method for diagnosing arteriosclerosis |
| WO2013050731A1 (en) * | 2011-10-05 | 2013-04-11 | The Binding Site Group Limited | Prognostic method for diabetes |
| CA2771954A1 (en) * | 2012-03-20 | 2013-09-20 | Matthew Simon Byers | Pneumonia biomarkers |
| US20190025328A1 (en) * | 2015-10-27 | 2019-01-24 | Abbott Laboratories | Troponin i and soluble urokinase receptor detection for determining the risk of cardiovascular disease |
| US20190307405A1 (en) * | 2018-04-10 | 2019-10-10 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
| CN111254228A (en) * | 2020-05-06 | 2020-06-09 | 上海思路迪医学检验所有限公司 | Kit for detecting novel coronavirus and influenza virus |
Non-Patent Citations (2)
| Title |
|---|
| 郝梦 等: "新型冠状病毒性肺炎危重型患者2例凝血功能指标分析", 宁夏医学杂志, vol. 42, no. 6, pages 495 * |
| 黄冰峰 等: "新冠肺炎COVID-19医学影像诊断和分子检测", 基因组学与应用生物学, vol. 39, no. 6, pages 2897 - 2901 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111681768A (en) | 2020-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petta et al. | Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations | |
| Knichwitz et al. | Continuous intramucosal PCO2 measurement allows the early detection of intestinal malperfusion | |
| Swift | Direct measurement of alcohol and its metabolites | |
| Cataldi et al. | Cystatin C in healthy women at term pregnancy and in their infant newborns: relationship between maternal and neonatal serum levels and reference values | |
| Homi et al. | Pulse oximetry in a cohort study of sickle cell disease | |
| CN113241187A (en) | Diagnostic kit | |
| Hatherill et al. | Gastric tonometry in septic shock | |
| Chase et al. | High-normal blood pressure and early diabetic nephropathy | |
| Parwanto et al. | Coronavirus disease 2019 (COVID-19): A case report in a patient with diabetic ketoacidosis and hypertension | |
| Fauchère et al. | Agreement between capillary and arterial lactate in the newborn | |
| Lopez et al. | Detection of carbon dioxide thresholds using low-flow sidestream capnography in ventilated preterm infants | |
| Moemen | Prognostic categorization of intensive care septic patients | |
| Modi et al. | The influence of postnatal respiratory adaptation on sodium handling in preterm neonates | |
| Almiş et al. | Mean platelet volume in hepatitis A | |
| Patil et al. | Study of serum magnesium levels in patients admitted with sepsis in Intensive Care Unit | |
| Ramos-Machado et al. | Sleep disorders and endothelial dysfunction in children with sickle cell anemia | |
| Dix et al. | Early end-tidal carbon monoxide levels, patency of the ductus arteriosus and regional cerebral oxygenation in preterm infants | |
| Tsukahara et al. | Urinary N‐acetyl‐beta‐D‐glucosaminidase excretion in term and preterm neonates | |
| Coban et al. | Can Renal Resistive Index Be Used As An Early Predictor of Acute Kidney Injury at Paediatric Intensive Care Units? | |
| Oberger et al. | Blood gases and acid-base balance in children with bronchial asthma | |
| RU2825705C1 (en) | METHOD FOR PREDICTION OF LETHAL OUTCOME IN SARS-CoV-2-ASSOCIATED PNEUMONIA | |
| Willis et al. | The validity of oxygen content calculations | |
| McKiel et al. | Siliconized vs nonsiliconized evaluated blood-collection tubes for free thyroxin measurements. | |
| Kallenahalli et al. | Can Noninvasive Oxygen Saturation Index Match Invasive Oxygenation Index to Monitor Respiratory Disease in Critically Ill Children?—A Prospective Study | |
| Chen et al. | Two different tests for total bilirubin in neonates and infants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |